TIDMTED 
 
RNS Number : 0992Q 
Tepnel Life Sciences PLC 
03 April 2009 
 

Tepnel Life  Sciences plc 
3 April 2009 
For Immediate Release 
 
 
Recommended acquisition 
of 
Tepnel Life Sciences plc ("Tepnel") 
by 
Gen-Probe Incorporated ("Gen-Probe") 
to be effected by means of a scheme of arrangement under Part 26 of the 
Companies Act 2006 
 
 
Result of First Court Hearing (to sanction the Scheme) 
The Tepnel Board is pleased to announce that the High Court of Justice in 
England and Wales has today sanctioned the Scheme by which the Acquisition of 
Tepnel by Gen-Probe is being implemented. 
In order for the Scheme to become effective in accordance with its terms, the 
Court will now need to confirm the associated Reduction at the Second Court 
Hearing which is expected to take place on 7 April 2009. Subject to the Scheme 
receiving the confirmation of the Court on that date, the Effective Date of the 
Scheme is expected to be 8 April 2009. 
It is also expected that the listing of and dealings in Tepnel Shares will be 
suspended with effect from 7.00 a.m. on 7 April 2009 and that the listing of 
Tepnel Shares on AIM will be cancelled with effect from 7.00 a.m. on 8 April 
2009. The consideration due to Scheme Shareholders will be sent no later than 14 
days after the Effective Date. 
Any capitalised term used but not defined in this announcement has the same 
meaning as is given to it in the Scheme document sent to Shareholders on 21 
February 2009. 
For further information: 
Tepnel Life Sciences plc 
Ben Matzilevich, Chief Executive Officer 
Michael Slater, Group Finance Director 
Carol Smith, Group Marketing Communications Manager 
Tel: 0161 946 2200 
Capital MS&L 
Mary Clark or Joanna Whineray 
Tel: +44 20 7307 5330 
Seymour Pierce Limited 
Mark Percy 
Tom Sheldon 
Christopher Wren 
Tel: +44 20 7107 8000 
Seymour Pierce, which is authorised and regulated by the Financial Services 
Authority, is acting exclusively for Tepnel and no one else in connection with 
the Offer and will not be responsible to anyone other than Tepnel for providing 
the protections afforded to clients of Seymour Pierce or for providing advice in 
connection with the Offer or any matter referred to herein. 
Merrill Lynch is acting for Gen-Probe in connection with the Offer and no one 
else and will not be responsible to anyone other than Gen-Probe for providing 
the protections afforded to clients of Merrill Lynch or for providing advice in 
relation to the Offer, or any matter referred to herein. 
Dealing Disclosure Requirements 
Under the provisions of Rule 8.3 of the Code, if any person is, or becomes, 
"interested" (directly or indirectly) in 1 per cent. or more of any class of 
"relevant securities" of Tepnel, all "dealings" in any "relevant securities" of 
Tepnel (including by means of an option in respect of, or a derivative 
referenced to, any such "relevant securities") must be publicly disclosed by no 
later than 3.30 p.m. (London time) on the Business Day following the date of the 
relevant transaction. This requirement will continue until the date on which the 
Scheme becomes effective or lapses or on which the "offer period" otherwise 
ends. If two or more persons act together pursuant to an agreement or 
understanding, whether formal or informal, to acquire an "interest" in "relevant 
securities" of Tepnel, they will be deemed to be a single person for the purpose 
of Rule 8.3. 
Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant 
securities" of Tepnel by Gen-Probe or Tepnel, or by any of their respective 
"associates", must be disclosed by no later than 12.00 noon (London time) on the 
Business Day following the date of the relevant transaction. 
A disclosure table, giving details of the companies in whose "relevant 
securities" "dealings" should be disclosed, and the number of such securities in 
issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk. 
"Interests in securities" arise, in summary, when a person has long economic 
exposure, whether conditional or absolute, to changes in the price of 
securities. In particular, a person will be treated as having an "interest" by 
virtue of the ownership or control of securities, or by virtue of any option in 
respect of, or derivative referenced to, securities. 
Terms in quotation marks are defined in the Code, which can also be found on the 
Panel's website. If you are in any doubt as to whether or not you are required 
to disclose a "dealing" under Rule 8, please contact an independent financial 
adviser authorised under the Financial Services and Markets Act 2000, consult 
the Panel's website at www.thetakeoverpanel.org.uk or contact the Panel on 
telephone number +44 (0) 20 7638 0129; fax +44 (0) 20 7236 7013. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCEAELDEEFNEFE
Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Ted Baker Charts.
Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Ted Baker Charts.